17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of 17-AAG and irinotecan in
treating patients with locally advanced or metastatic solid tumors. Drugs used in
chemotherapy, such as 17-AAG and irinotecan, work in different ways to stop the growth of
tumor cells either by killing the cells or by stopping them from dividing. Giving more than
one drug (combination chemotherapy) may kill more tumor cells.